Pharma Focus Asia

KBI Biopharma Invests $150 Millionto Expand Commercial Manufacturing Facility in North California

Introduction:
KBI Biopharma, Inc, plans to open a new facility for commercial manufacturing. The manufacturing site involves an investment of US$150 million. The facility will be located atResearch Triangle Park (RTP) in North Carolina.

Features:
The manufacturing facility covering an area of 140,000-sq-ftconsists of the latest innovation in automation and digitalisation. The new site consists of up to six 2,000-L, single-use bioreactor systems, and associated harvest and purification equipmentcapable of producing more than 100 commercial batches annually.

The new facility is designed with advanced technologies including data collection systems like batch records, electronic logbooks, paperless materials management, and laboratory information management systems for quality control data management. These advanced tools are useful for real-time processing, product quality monitoring, and future artificial intelligence technology adoption.

This facility will be used as acommercialisation optionfor both KBI’s existing and future partners thus increasing the client’scommercialisation strategies.

Thenew state-of-the-art facility is expected to complete its construction and start its operations in the first quarter of 2022.

Specifications:

NameKBI Biopharma
TypeNew Manufacturing Facility Construction
BudgetUS$150 million
YearQ1 2022

 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference